{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:42:35Z","timestamp":1790674955891,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003825","name":"Magyar Tudom\u00e1nyos Akad\u00e9mia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003825","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018818","name":"National Research, Development and Innovation Office","doi-asserted-by":"publisher","award":["NKFIH\/FK_12443"],"award-info":[{"award-number":["NKFIH\/FK_12443"]}],"id":[{"id":"10.13039\/501100018818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018818","name":"National Research, Development and Innovation Office","doi-asserted-by":"publisher","award":["NVKP_16-1-2016-004"],"award-info":[{"award-number":["NVKP_16-1-2016-004"]}],"id":[{"id":"10.13039\/501100018818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.urolonc.2020.09.005","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T09:05:29Z","timestamp":1602234329000},"page":"296.e11-296.e19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy"],"prefix":"10.1016","volume":"39","author":[{"given":"T.","family":"Szarvas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Csizmarik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"V\u00e1radi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Fazekas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"H\u00fcttl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Nyir\u00e1dy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Gr\u00fcnwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tschirdewahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sevcenco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Maj-Hes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2020.09.005_bib0001","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2020.09.005_bib0002","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2020.09.005_bib0003","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.09.005_bib0004","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.ctrv.2015.08.002","article-title":"Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer","volume":"41","author":"Buttigliero","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.urolonc.2020.09.005_bib0005","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0304-3835(01)00772-8","article-title":"MMP-7 (matrilysin) accelerated growth of human umbilical vein endothelial cells","volume":"177","author":"Huo","year":"2002","journal-title":"Cancer Lett"},{"key":"10.1016\/j.urolonc.2020.09.005_bib0006","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1742-4658.2010.07919.x","article-title":"Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting","volume":"278","author":"Gialeli","year":"2011","journal-title":"FEBS J"},{"key":"10.1016\/j.urolonc.2020.09.005_bib0007","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/153537020623100103","article-title":"Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis","volume":"231","author":"Ii","year":"2006","journal-title":"Exp Biol Med"},{"key":"10.1016\/j.urolonc.2020.09.005_bib0008","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11255-015-1185-8","article-title":"Validation of the diagnostic and prognostic relevance of serum MMP-7 levels in renal cell cancer by using a novel automated fluorescent immunoassay method","volume":"48","author":"Niedworok","year":"2016","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.urolonc.2020.09.005_bib0009","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1158\/1078-0432.CCR-1157-03","article-title":"Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival","volume":"10","author":"Jones","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2020.09.005_bib0010","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/path.1277","article-title":"Association of trypsin expression with tumour progression and matrilysin expression in human colorectal cancer","volume":"199","author":"Yamamoto","year":"2003","journal-title":"J Pathol"},{"key":"10.1016\/j.urolonc.2020.09.005_bib0011","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nrurol.2011.44","article-title":"Matrix metalloproteinases and their clinical relevance in urinary bladder cancer","volume":"8","author":"Szarvas","year":"2011","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2020.09.005_bib0012","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/(SICI)1098-2744(199601)15:1<57::AID-MC8>3.0.CO;2-P","article-title":"Matrilysin expression in human prostate carcinoma","volume":"15","author":"Knox","year":"1996","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.urolonc.2020.09.005_bib0013","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccr.2005.04.013","article-title":"MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL","volume":"7","author":"Lynch","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urolonc.2020.09.005_bib0014","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/ijc.25454","article-title":"Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy","volume":"128","author":"Szarvas","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2020.09.005_bib0015","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.oraloncology.2009.02.008","article-title":"Matrix metalloproteinase-7 and -13 expression associate to cisplatin resistance in head and neck cancer cell lines","volume":"45","author":"Ansell","year":"2009","journal-title":"Oral Oncol"},{"key":"10.1016\/j.urolonc.2020.09.005_bib0016","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1111\/j.1349-7006.2008.00922.x","article-title":"Predictive value of MMP-7 expression for response to chemotherapy and survival in patients with non-small cell lung cancer","volume":"99","author":"Liu","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1016\/j.urolonc.2020.09.005_bib0017","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/bju.14415","article-title":"Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer","volume":"122","author":"Szarvas","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2020.09.005_bib0018","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.09.005_bib0019","article-title":"Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer","author":"Szarvas","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2020.09.005_bib0020","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1371\/journal.pone.0004728","article-title":"The role of MMP7 and its cross-talk with the FAS\/FASL system during the acquisition of chemoresistance to oxaliplatin","volume":"4","author":"Almendro","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.urolonc.2020.09.005_bib0021","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1007\/s11033-008-9422-1","article-title":"Chronic exposure to exogenous matrilysin induces chemoresistance and enhances Bcl-2 expression in A549 lung adenocarcinoma cells","volume":"36","author":"Liu","year":"2009","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.urolonc.2020.09.005_bib0022","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/annonc\/mdx155","article-title":"Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study","volume":"28","author":"Conteduca","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2020.09.005_bib0023","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1200\/JCO.2016.70.1961","article-title":"Clinical sgnificance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with etastatic castration-resistant prostate cancer treated with first-and second-line abiraterone and enzalutamide","volume":"35","author":"Antonarakis","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.09.005_bib0024","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1556\/650.2019.31315","article-title":"Molecular subtypes and perspectives of targeted therapies in prostate cancer","volume":"160","author":"Szarvas","year":"2019","journal-title":"Orv Hetil"},{"key":"10.1016\/j.urolonc.2020.09.005_bib0025","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/2159-8290.CD-17-0937","article-title":"Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer","volume":"8","author":"Annala","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.urolonc.2020.09.005_bib0026","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/bju.13493","article-title":"Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy","volume":"119","author":"Heck","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2020.09.005_bib0027","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/1756-9966-28-132","article-title":"MMP7 expression regulated by endocrine therapy in ER\u03b2-positive colon cancer cells","volume":"28","author":"Fang","year":"2009","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920304361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920304361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:22:21Z","timestamp":1778588541000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143920304361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S1078143920304361"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.09.005","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}